Prices delayed by at least 15 minutes | Print
Rtw Biotech Opportunities LTD
ORD NPVOpen
$2.43
Previous close
$2.44
Trade high
$2.50
Estimated NAV
2.67
Year high
$2.64
Year low
$1.82
Premium / Discount
-8.61%
Market capitalisation
$787.49 mn
Volume
1,038,075
Dividend yield
–
Ongoing charge
1.7%
ISIN
GG00BKTRRM22
Share price
Net asset value (NAV)
| Estimated NAV | 2.67 |
|---|---|
| Latest actual NAV | 2.67 |
| Latest actual NAV date | 31 October 2026 |
| 12m average premium/discount | -14.57% |
Top 10 holdings
| Holdings 31/12/2025 | % of assets |
|---|---|
| PTC Therapeutics Inc | 11.65 |
| CORXEL Pharmaceuticals | 6.23 |
| Stoke Therapeutics Inc | 5.18 |
| UroGen Pharma Ltd | 5.03 |
| Insmed Inc | 3.90 |
| Kailera Therapeutics | 3.41 |
| Tarsus Group PLC | 2.80 |
| Immatics NV Ordinary Shares | 2.74 |
| argenx SE | 2.19 |
| Madrigal Pharmaceuticals Inc | 1.92 |
Investment objective
The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Morningstar ratingTM
News
Recent trades
| Date | Time | Price | Quantity | Value |
|---|---|---|---|---|
| 16/11/2026 | 04:35:26 | 2.47 | 31,119 | 76,863.93 |
| 16/11/2026 | 04:24:50 | 2.47 | 6 | 14.82 |
| 16/11/2026 | 04:24:45 | 2.46 | 141 | 346.86 |
| 16/11/2026 | 04:24:44 | 2.46 | 140 | 344.40 |
| 16/11/2026 | 04:24:42 | 2.47 | 480 | 1,185.60 |